No published articles yet for this condition. Check back soon.
Research across Colonic Diseases
Related studies from across the Colonic Diseases family.
5 trials tracked for colitis: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 41 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical trials demonstrate that specific interventions significantly improve clinical outcomes in patients with colitis. At week 6, a statistically significant increase in the number of participants achieving clinical response was observed compared to placebo (p<0.001) 1. This is further supported by data showing significant improvements in clinical response at week 6 for those receiving 130 mg of ustekinumab (p=0.002) 3.
Longer-term outcomes also show statistically significant improvements over placebo. Clinical remission was achieved significantly more often at week 8 (p=0.009) 1 and at week 44 (p=0.040) 2. Additionally, clinical response rates remained significantly higher than placebo at week 8 (p<0.001) 1 and at week 44 (p=0.033) 2.
In a maintenance study evaluating patients who were already in remission on ustekinumab at week 0, the difference in clinical remission at week 44 compared to placebo did not reach statistical significance (p=0.189) 2.
AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Colonic Diseases family.
